Physician profile
Giovanni Velez
NPI 1326366782
$9,011.23
in general payments reported to CMS, 2019-2025
47 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,751 · 2020: $1,228 · 2021: $1,413 · 2022: $1,696 · 2023: $897 · 2024: $641 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,923.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $991.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $937.08 | 2019-2025 | Yeztugo |
| Astrazeneca Pharmaceuticals Lp | $854.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $710.11 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $612.07 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $602.62 | 2019-2025 | Jardiance |
| Pfizer INC. | $548.13 | 2019-2025 | |
| Novo Nordisk INC | $537.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pinnacle Biologics, INC | $459.83 | 2022 | |
| Amgen INC. | $275.10 | 2019-2025 | Repatha, Otezla, Repatha |
| Viiv Healthcare Company | $268.60 | 2022-2025 | Apretude |
| Amarin Pharma, INC. | $175.90 | 2019-2022 | |
| Abbott Laboratories | $158.52 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.38 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $146.81 | 2023-2025 | Cologuard Collection Kit |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Giovanni Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.